A Pharmaceutical entity from India is looking for strategic investment opportunities in API and Formulation entities in India.

Posted By - Investment Banker Posted date - 29/08/2020

TARGET BRIEF

A pharmaceutical client is looking out for acquiring a GMP / MHRA approved/certified Formulation plant having a capacity of approx 200-250 MT per month and an API plant having capacity of producing volume building API’s ( paracetamol, ibuprofen, Metformin) of around 300 – 500 MT per month anywhere in India. The firm has established world-class manufacturing facilities by leveraging state-of-the-art technology, incorporating best practices and adhering to stringent regulatory compliance. The Plants are approved by prestigious US FDA, UK MHRA, Australian TGA and other foreign health authorities. R&D capabilities include dossier development, chemical synthesis, process optimization, formulation development, analytical development.

Proposal
Icon

Industry

Pharmaceuticals

Icon

Sub Industry

Integrated

Icon

Deal Size

INR 100 - 200 Cr

Icon

Funding Sources

Cash,Fresh Debt

Icon

Synergies Sought

Manufacturing Strengths (Production/Operations)

Icon

Deal Option

Complete Buyout

Open For Distressed Assets

Icon

Target Location

12, 9, 14, 15, 33, 16, 1, 17, 6, 4, 18, 19, 20, 10, 21, 7, 2, 22, 23, 24, 25, 26, 5, 3, 31, 30, 29, 28, 13, 8, 27

Icon

Type

General & Beta Lactum

Icon

Product

paracetamol, ibuprofen, Metformin

Icon

Export

Yes

Icon

Formulation Type

Oral Solids, Liquids, Parenteral

Icon

Type

Branded

Icon

Therapeutic Area

Chronic, Acute

Business Operation Information
Icon

Industry

Pharmaceuticals

Icon

Sub-Industry

Bulk Drug manufacturing

Icon

Division

Icon

Division`s Buyers/Customers

Business Documents

Recommended Deals